DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
5.71
+0.04 (0.71%)
Jan 17, 2025, 4:00 PM EST - Market closed
DiaMedica Therapeutics Employees
As of December 31, 2023, DiaMedica Therapeutics had 19 total employees, including 18 full-time and 1 part-time employees. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,142,368
Market Cap
244.16M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
DMAC News
- 6 weeks ago - DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia - Business Wire
- 2 months ago - DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
- 2 months ago - DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Business Wire
- 2 months ago - DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - Business Wire
- 3 months ago - DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
- 4 months ago - DiaMedica Therapeutics Upcoming Conference Participation - Business Wire